Degrasyn (WP1130)

For research use only.

Catalog No.S2243

22 publications

Degrasyn (WP1130) Chemical Structure

Molecular Weight(MW): 384.27

Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 260 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 1990 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Degrasyn (WP1130) has been cited by 22 publications

Purity & Quality Control

Choose Selective Bcr-Abl Inhibitors

Biological Activity

Description Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). Degrasyn (WP1130) induces apoptosis and blocks autophagy.
Features WP1130 has an advantage over imatinib mesylate in that its activity is not inhibited by a variety of Abl kinase mutations, including T315I.
Targets
DUB [1]
(Cell-free assay)
Bcr-Abl [1]
(Cell-free assay)
1.8 μM
In vitro

In addition to inducing rapid down-regulation of Bcr/Abl without affecting Bcr or c-Abl, WP1130 also regulates the stability of Jak2 and c-Myc without affecting other kinases (HER1, HER2, c-Kit, FAK, ERK1, ERK2, Akt, Btk, Src and Src-related kinases) or transcription factors (wild-type p53, STAT1, STAT3, STAT5, c-Jun, NF-κB, and Max). Unlike adaphostin and Trisenox, WP1130 induces down-regulation of Bcr/Abl within 60 minutes. WP1130 is more effective in inducing apoptosis of myeloid and lymphoid tumor cells with IC50 of ~0.5-2.5 μM compared with normal CD34+ hematopoietic precursors, dermal fibroblasts, or endothelial cells with IC50 of ~5-10 μM. WP1130 (5 μM) specifically and rapidly down-regulates both wild-type and T315I mutant Bcr/Abl protein without affecting bcr/abl gene expression or engaging the proteasomal degradation pathway in chronic myelogenous leukemia (CML) cells, accompanied by induction of apoptosis. WP1130 is more effective in reducing leukemic cell colony formation compared with normal progenitor cells, and effective against primary leukemic cells harboring the T315I mutation. [1] WP1130 induces rapid proteasomal-dependent degradation of c-Myc protein in MM-1 multiple myeloma and other tumor cell lines, correlated with tumor growth inhibition. [2] Unlike AG490, WP1130 acts as a partly selective deubiquitinase (DUB) inhibitor to induce a rapid and marked accumulation of polyubiquitinated (K48/K63-linked) proteins into juxtanuclear aggresomes without affecting proteasome activity. WP1130 (5 μM) directly inhibits DUB activity of USP9x, USP5, USP14, UCH-L1, and UCH37, but not UCH-L3, resulting in downregulation of antiapoptotic and upregulation of proapoptotic proteins, such as MCL-1 and p53. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human Mino cells M2LJWmN6fG:2b4jpZ4l1gSCjc4PhfS=> MUG3NkBp MVnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNbY5wKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD64JO69VQ>? NUX1S25pOjR2NUewPVE>
human MM1 cells Ml;HSpVv[3Srb36gZZN{[Xl? MkG4NlQhfG9iN{KgbJJ{ MUnBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPTUGgZ4VtdHNiYX\0[ZIhOjRidH:gO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2xJO69VQ>? M4PJNVIzODN4MkGz
human MM1S cells MkC1R5l1d3SxeHnjbZR6KGG|c3H5 MWi3NkBp NVPjSHc4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVU1zUzDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvOiEQvF2= M{nEclI1PDV5MEmx
human U266 cells MnjySpVv[3Srb36gZZN{[Xl? NInZcokzPCC2bzC3NkBpenN? NIW1b3BCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVNlY3KGOnbHzzJIFnfGW{IEK0JJRwKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5|IN88US=> M1PLeVIzODN4MkGz
human OCI-My4 cells MmjZSpVv[3Srb36gZZN{[Xl? M3jjTVI1KHSxIEeyJIhzew>? NUTuR5JiSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gU2NKNU27NDDj[YxteyCjZoTldkAzPCC2bzC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuOUDPxE1? NVjSeFIxOjJyM{[yNVM>
human A375 cells MXzDfZRwfG:6aXPpeJkh[XO|YYm= M3jvb|czKGh? MmTUR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyPUGuO{DPxE1? MVSyOFQ2PzB7MR?=
human K562 cells M1ni[mN6fG:2b4jpZ4l1gSCjc4PhfS=> Mnr5O|IhcA>? M1PKd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGs2PjJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yMlQh|ryP M{LIU|I1PDV5MEmx
human Z138 cells NEj1eXJHfW6ldHnvckBie3OjeR?= M1L5ZVEhcA>? M{HkdGlvcGmkaYTpc44hd2ZiVVPIMWwyKGmwIHj1cYFvKFpzM{igZ4VtdHNiYX\0[ZIhOSCqcjDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrczygTWM2OD1|IN88US=> NV7nNGVSOjN5OUGwO|Y>
human Z138 cells NHnRV5ZHfW6ldHnvckBie3OjeR?= M{G2NlEvOjVidH:gOUB2VQ>? NGLZbW81KGh? NXfkVHFiUW6qaXLpeIlwdiCxZjDVd5A6gCCrbjDoeY1idiCcMUO4JINmdGy|IIXzbY5oKEiDLWXiJJZqdnmuLYP1cIZwdmViYYOgd5Vje3S{YYTlJIF1KDFwMkWgeI8hPSC3TTDh[pRmeiB2IHjyd{BjgSCrbX31co9jdG:2dHnu[{BidmGueYPpdy=> NUWyOYlWOjR2NUewPVE>

... Click to View More Cell Line Experimental Data

In vivo Administration of WP1130 inhibits the growth of K562 tumors as well as both wildtype Bcr/Abl and T315I mutant Bcr/Abl-expressing BaF/3 cells transplanted into nude mice. [1] Consistent with the down-regulation of c-Myc, WP1130 displays potent inhibitory activity against A375 melanoma tumors established in nude mice. [2]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: BV173, BV173R, K562, and BaF/3
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method: Cells are treated with increasing concentrations of WP1130 (0.08-10 μM) in 96-well plates. Plates are incubated at 37 °C for 72 hours, after which 20 μL of MTT reagent is added, and the plates are incubated at 37 °C for another 2 hours. Cells are lysed with 100 μL lysis buffer (20% sodium dodecyl sulfate [SDS] in 50% N, N-dimethylformamide adjusted to pH 4.7 with 80% acetic acid and 1 M hydrochloric acid; final concentration of acetic acid is 2.5% and hydrochloric acid is 2.5%) and incubated for 6 hours. The optical density of each sample at 570 nm is determined with a SPECTRA MAX M2 plate reader.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Swiss Nu/Nu mice transplanted with K562 tumor cells, BaF/3wt cells, or BaF/3/T315I cells
  • Dosages: ~40 mg/kg every other day
  • Administration: Injected intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 77 mg/mL (200.37 mM)
Water Insoluble
Ethanol '18 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 384.27
Formula

C19H18BrN3O

CAS No. 856243-80-6
Storage powder
in solvent
Synonyms N/A
Smiles CCCC(C1=CC=CC=C1)NC(=O)C(=CC2=NC(=CC=C2)Br)C#N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcr-Abl Signaling Pathway Map

Bcr-Abl Inhibitors with Unique Features

Related Bcr-Abl Products

Tags: buy Degrasyn (WP1130) | Degrasyn (WP1130) supplier | purchase Degrasyn (WP1130) | Degrasyn (WP1130) cost | Degrasyn (WP1130) manufacturer | order Degrasyn (WP1130) | Degrasyn (WP1130) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID